Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts.

ABSTRACT:

Background

Allogeneic hematopoietic cell transplantation is indicated for refractory hematologic cancer and some nonmalignant disorders. Survival is limited by recurrent cancer and organ toxicity.

Objective

To determine whether survival has improved over the past decade and note impediments to better outcomes.

Design

The authors compared cohorts that had transplants during 2003 to 2007 versus 2013 to 2017. Survival outcome measures were analyzed, along with transplant-related complications.

Setting

A center performing allogeneic transplant procedures.

Participants

All recipients of a first allogeneic transplant during 2003 to 2007 and 2013 to 2017.

Intervention

Patients received a conditioning regimen, infusion of donor hematopoietic cells, then i

SUBMITTER: McDonald GB 

PROVIDER: S-EPMC7847247 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature